Summary
The purpose of this study is to check how well an investigational antiemetic drug called LY35327021 works and how safe it is for controlling nausea and vomiting caused by chemotherapy.
You may be eligible for this study if you have not receive chemotherapy treatment (chemotherapy-naive) but are planned to receive AC or cisplatin-based chemotherapy greater than or equal to 70mg/m2 on Day 1 of each cycle, with no multiple administrations during the CINV observation period, from Day 2 to Day 5 of each cycle.
Eligible participants will be randomly allocated to one of two arms - either experimental or placebo comparator.
Prior to chemotherapy treatment, participants will receive either LY3537021 or a placebo depending on the arm they are allocated to. These will both be administeded as an injection, and will be given with standard of care antiemetic therapies orally, intravenously or transdermally.
Participants who join this study will be in it until all parts are finished, which could take about 2 months.